Clozapine IM and Aggression in Schizophrenic Patients

Schizophrenia Clinical Trial

Official title:

Intramuscular Clozapine in the Management of Aggression in Schizophrenic Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00189995
• Other study ID #: BMHC-4000
• Status: Withdrawn
• Phase: Phase 3
• First received: September 11, 2005
• Last updated: July 23, 2013

Study information

• Verified date: October 2005
• Source: Beersheva Mental Health Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Interventional

Clinical Trial Summary

Aggressive, persistent aggression and impulsive behavior are frequently observed in schizophrenic patients. According to some researchers "more than 50% of all psychiatric patients and 10% of schizophrenic patients show aggressive symptoms varying from threatening behavior and agitation to assault"(1). It is a common cause of psychiatric admission and is a therapeutic issue. The treatment of these symptoms is a clinical problem for both patients and staff. Violent behavior, a major detrimental factor in stigmatization of the mentally ill, also poses physical danger for the patients themselves. Current pharmacotherapy of pathologic aggression involves the use of multiple agents (typical and atypical antipsychotics, benzodiazepines, mood stabilizers, beta-blockers, antiandrogenic hormones, and selective serotonin reuptake inhibitors) on empiric basis, with varying degrees of response (2-6). Unfortunately, these approaches lead to numerous side effects. Poor or noncompliance with pharmacotherapy makes it difficult to choose the appropriate preparation. Currently, typical neuroleptics are still the first choice in treating acute aggressive symptoms, while risperidone and olanzapine could be alternatives (5-7). Typical depot neuroleptics should be considered in cases where medication compliance is a problem. Most clinical information on treating of aggression has been collected about atypical neuroleptics, particularly regarding clozapine.

Clozapine is indicated in psychotic state and/or in drug-resistant schizophrenic patients. According to the FDA - it is the drug of choice in suicidal and aggressive patients, due-to psychotic state. It was found helpful in nearly 30% of resistant schizophrenic patients. Concerning the parenteral administration of clozapine - very little data is available today.

This study aims to investigate efficacy and safety (psychopathology, and side effects) of parenteral clozapine in treatment of aggressive behavior in schizophrenic patients in a double-blind trial.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• schizophrenic, schizoaffective, or schizophreniform according to DSM-IV

• treatment-resistant

• presenting pathologic violent-aggressive behavior on admission

• at risk for self damage

• age: 18-65

• patient is not participating in any other study at time of this study

• minimal score of 70 on PANSS

• prior resistance to at least 2 different classes of neuroleptics

• OAS scores of at least 4 points in physical aggression sections and at least 2 points in verbal aggression section

Exclusion Criteria:

• neutropenia or any other abnormal CBC result

• myeloproliferative disease

• chronic physical diseases such as liver, renal or cardiac diseases

• history of alcohol or drug abuse

• history of drug induced granulocytopenia/agranulocytosis

• alcoholic/drug psychosis or intoxication

• carbamazepine or other bone marrow suppressor treatment

• uncontrolled epilepsy

• paralytic ileus

• hypersensitivity to clozapine

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Aggression
• Schizophrenia

Intervention

Drug:
• clozapine

• haloperidol

Locations

Country	Name	City	State
Israel	Beersheva Mental Health Center	Beersheva
Israel	Nes Ziona Medical Center	Nes Ziona

Sponsors (1)

Lead Sponsor	Collaborator
Beersheva Mental Health Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive and Negative Syndrome Scale
Primary	Overt Aggression Scale